{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:30:42Z","timestamp":1791196242553,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":284,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.semnephrol.2023.151431","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:33:08Z","timestamp":1698683588000},"page":"151431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Role of Inflammation in Progression of Chronic Kidney Disease in Type 2 Diabetes Mellitus: Clinical Implications"],"prefix":"10.1016","volume":"43","author":[{"given":"Yasuhiro","family":"Oda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2023.151431_bib0001","doi-asserted-by":"crossref","first-page":"F1719","DOI":"10.1152\/ajprenal.00141.2013","article-title":"Macrophages directly mediate diabetic renal injury","volume":"305","author":"You","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0002","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.2015.162","article-title":"Macrophage-derived tumor necrosis factor-alpha mediates diabetic renal injury","volume":"88","author":"Awad","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0003","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","article-title":"Innate immunity in diabetic kidney disease","volume":"16","author":"Tang","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonzalez","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0005","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diabetes.48.4.855","article-title":"Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells","volume":"48","author":"Yerneni","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0006","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.272.28.17810","article-title":"Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress","volume":"272","author":"Lander","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0007","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1523-1755.2001.059002415.x","article-title":"Transcription factor-kappa B (NF-kappa B) and renal disease","volume":"59","author":"Guijarro","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0009","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.kint.2017.03.027","article-title":"Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice","volume":"92","author":"Zhang","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ki.2009.98","article-title":"Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy","volume":"76","author":"Lu","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0011","doi-asserted-by":"crossref","first-page":"e88894","DOI":"10.1371\/journal.pone.0088894","article-title":"Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells","volume":"9","author":"Yiu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0012","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.bbadis.2012.12.013","article-title":"Coagulation and coagulation signalling in fibrosis","volume":"1832","author":"Mercer","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0013","doi-asserted-by":"crossref","first-page":"33030","DOI":"10.1038\/srep33030","article-title":"Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice","volume":"6","author":"Waasdorp","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0014","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2337\/dc09-1799","article-title":"Increased Toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects","volume":"33","author":"Dasu","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0015","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1016\/S0021-9258(18)42137-0","article-title":"Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface","volume":"267","author":"Schmidt","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0016","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1681\/ASN.2010111210","article-title":"Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy","volume":"23","author":"Lin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0017","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.kint.2022.06.010","article-title":"Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease","volume":"102","author":"Shahzad","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0018","doi-asserted-by":"crossref","first-page":"13302","DOI":"10.1073\/pnas.0405449101","article-title":"Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor","volume":"101","author":"Kakoki","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0019","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1073\/pnas.1005144107","article-title":"Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice","volume":"107","author":"Kakoki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0020","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.kint.2016.06.018","article-title":"Exogenous kallikrein protects against diabetic nephropathy","volume":"90","author":"Liu","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0021","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0022","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0023","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0024","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0025","first-page":"S12","article-title":"Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney","author":"Ruiz-Ortega","year":"200282","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0026","doi-asserted-by":"crossref","first-page":"R208","DOI":"10.1152\/ajpregu.90521.2008","article-title":"Regulation of T-cell function by endogenously produced angiotensin II","volume":"296","author":"Hoch","year":"2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0027","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/ki.2013.387","article-title":"Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db\/db mice","volume":"85","author":"Reddy","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0028","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0029","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0030","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0031","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0032","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2023.151431_bib0033","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0034","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0035","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0036","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0037","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0038","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0039","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide vs. insulin glargine 100 U\/mL on kidney outcomes in participants with type 2 diabetes in SURPASS-4","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0040","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151431_bib0041","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/ndt\/gft224","article-title":"The Nrf2 pathway in the progression of renal disease","volume":"29","author":"Zoja","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0042","doi-asserted-by":"crossref","first-page":"11624","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0043","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0044","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0045","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151431_bib0046","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/ndt\/gfac242","article-title":"Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of AYAME study","volume":"38","author":"Nangaku","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0047","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI8609","article-title":"Salt-sensitive hypertension in endothelin-B receptor-deficient rats","volume":"105","author":"Gariepy","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0048","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.110.156570","article-title":"Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat","volume":"56","author":"Saleh","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0049","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151431_bib0050","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:43:20Z","timestamp":1748357000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0270929523001419"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151431","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Inflammation in Progression of Chronic Kidney Disease in Type 2 Diabetes Mellitus: Clinical Implications","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151431"}}